Drug factory · FDA FEI 1525864

Adare Pharmaceuticals, Inc.

845 Center Dr., Vandalia, OH, United States

United States: 1

Problems found, fixed voluntarily at FDA's last inspection, Feb 25, 2025.

Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.

8 drug inspections on record since 2009: 6 with no problems, 2 with problems fixed voluntarily, 0 with FDA action.

What it does, for whom

DrugRoleForNDC
CyclobenzaprineMakes it Amneal Pharmaceuticals 0115-1436, 0115-1437
Fenofibric AcidMakes it, tests it and packages it Rhodes Pharmaceuticals L.P. 42858-454, 42858-660
Potassium CationMakes it Adare Pharmaceuticals Inc, Caraco Pharmaceutical Laboratories, Ltd. 59917-102, 59917-103, 63304-076 +3
PropranololMakes it Breckenridge Pharmaceutical, Inc. 51991-817, 51991-818, 51991-819 +1

FDA inspection history

EndedResultProgramProblems noted
Feb 25, 2025Problems found, fixed voluntarilyDrug Quality Assurance1
Jan 25, 2019No problems foundDrug Quality Assurance—
Jul 11, 2018No problems foundBioresearch Monitoring—
May 19, 2017No problems foundDrug Quality Assurance—
Nov 16, 2012No problems foundDrug Quality Assurance—
Dec 21, 2011Problems found, fixed voluntarilyDrug Quality Assurance—
Jun 17, 2011No problems foundDrug Quality Assurance—
Nov 20, 2009No problems foundDrug Quality Assurance—

What inspectors wrote down

From FDA's Form 483 citations: conditions an investigator observed that may violate drug manufacturing rules, as FDA published them.

Feb 25, 2025 inspection

Registered with FDA for: analysis; api manufacture; manufacture; pack.